by Mark Curtis | May 25, 2015
. Welcome to your Update from the Clinic for the month of April. Mesenchymal stem cells took a hit as Athersys’ MultiStem came up short, missing its primary endpoint in a Phase 2 study investigating the cells for ischemic stroke. Juno Therapeutics continues to turn...
by Paul Krzyzanowski | May 21, 2015
. By now, many of you will have heard of Fujifilm’s USD$307 million purchase of Cellullar Dynamics International (CDI). This may seem like a major entry into the regenerative medicine (RM) space for a company that’s better known for its imaging technologies than...
by David Kent | Apr 16, 2015
. Last month, Nature published a comment by Edward Lanphier and colleagues, which foreshadows the publication of a study in which scientists have used new genome editing tools to modify the DNA of human embryos. Author David Cyranoski weighed in, suggesting that...
by Mark Curtis | Apr 13, 2015
. Welcome to your deal review for the month of March. Cellular Dynamics threw shareholders for a loop after making a seemingly hasty decision to sell the company off to Fujifilm in a $307* million deal. Merck and synthetic biology specialist Intrexon announced a...
by Mark Curtis | Apr 7, 2015
. Welcome to your Update from the Clinic for the month of March. Investors weren’t so keen on Neuralstem’s topline results in amyotropic lateral sclerosis (ALS). NeoStem’s follow-up data from its PreSERVE study in acute myocardial infarction (AMI) was somewhat...
by Stacey Johnson | Apr 3, 2015
. Last month (March 13), StemCellTalks held a symposium on diabetes and stem cell tourism to educate Toronto high school students about the field. (These events happen across Canada.) The morning session began with Dr. Elia Piccinini (University of Toronto) giving an...
Comments